Loading...
XKRX
005500
Market cap150mUSD
Jul 10, Last price  
18,270.00KRW
1D
1.67%
1Q
-0.92%
Jan 2017
-47.42%
Name

Samjin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:005500 chart
P/E
9.57
P/S
0.75
EPS
1,909.49
Div Yield, %
4.45%
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
5.62%
Revenues
309.13b
+0.25%
137,112,663,000147,996,742,000165,388,711,000200,410,515,000201,756,103,660185,702,080,230192,006,713,100201,305,289,860216,511,471,520239,312,893,940245,271,927,860260,016,571,280241,926,177,090235,164,889,000250,070,356,000274,031,808,000292,128,534,000308,349,934,000309,133,531,000
Net income
24.17b
-38.39%
6,434,603,0006,731,815,0007,044,974,00010,477,195,0007,062,463,89010,638,443,4907,878,193,57020,716,717,57027,043,171,46030,174,331,51035,795,824,75025,526,185,48011,880,757,00027,879,308,00028,404,156,00021,893,836,00018,908,448,00039,232,983,00024,169,890,000
CFO
22.23b
-41.73%
-5,744,629,000-1,503,696,0002,135,391,00016,835,715,00012,670,311,56033,931,501,2207,374,337,48032,406,391,92018,935,641,49048,657,842,14037,283,674,16030,081,823,68023,633,082,80023,860,500,00023,967,390,00017,293,228,0008,333,561,00038,152,788,00022,233,195,000
Dividend
Dec 29, 2025800 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
URL
https://www.samjinpharm.co.kr/
IPO date
Jun 18, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT